Table 4.

Occurrence of DAIDS Grade 3/4 ALT/AST and hepatic serious adverse events (SAEs) among -LD and +LD TPV/r 500/200 mg BID patients

	-LD patients1		+LD patients1
ALT/AST DAIDS >22	Hepatic SAE		Hepatic SAE
	Yes	No	Yes	No
Yes	3	107	1	29
No	6	970	4	141

¹Thirty-two patients had missing information and were unable to be classified into one of the two risk groups; none of these patients experienced a hepatic SAE.

+LD = patients with underlying liver disease (baseline evidence of active HBV/HCV infection or ALT/AST Grade >1); -LD = patients with no apparent liver disease (absence of active HBV/HCV infection and ALT/AST Grade ≤ 1); ALT = alanine aminotransferase; AST = aspartate aminotransferase; DAIDS = Division of AIDS; HBV = hepatitis B virus; HCV = hepatitis C virus; TPV/r = ritonavir-boosted tipranavir

²ALT/AST on treatment DAIDS Grade 3/4